natgillin/translations-raw huggingface dataset:
Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.
Na osnovi farmakološkog mehanizma djelovanja hidroklorotiazida može se zaključiti da njegova primjena u drugom i trećem tromjesečju trudnoće može ugroziti feto-placentalnu perfuziju i uzrokovati nuspojave u fetusa i novorođenčadi poput žutice, poremećaja ravnoteže elektrolita i trombocitopenije.
No dosage adjustment of Ifirmacombi is necessary in older people.
Nije potrebno prilagođavati dozu lijeka Ifirmacombi u starijih osoba.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
Stenoza aortnog i mitralnog zaliska, opstruktivna hipertrofična kardiomiopatija:
Other medicines and Ifirmacombi
Drugi lijekovi i Ifirmacombi
What Ifirmacombi contains - The active substances are irbesartan and hydrochlorothiazide.
Što Ifirmacombi sadrži - Djelatne tvari su irbesartan i hidroklorotiazid.
There is no experience regarding the administration of Ifirmacombi in patients with recent kidney transplantation.
Nema iskustava s primjenom lijeka Ifirmacombi u bolesnika kojima je nedavno transplantiran bubreg.
Based on its pharmacodynamic properties, Ifirmacombi is unlikely to affect the ability to drive and use machines.
Na temelju farmakodinamičkih svojstava, nije vjerojatno da će Ifirmacombi utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Table 3: Adverse reactions reported with the use of hydrochlorothiazide alone Investigations
Tablica 3: Nuspojave prijavljene pri primjeni samo hidroklorotiazida Pretrage
Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood components.
Oko 96% irbesartana veže se za proteine u plazmi sa zanemarivim vezanjem za krvne stanice.
increases in blood urea nitrogen (BUN), creatinine and creatine kinase decreases in serum potassium and sodium
porast koncentracije BUN-a (dušik iz ureje u krvi), kreatinina i kreatin kinaze smanjenje koncentracije kalija i natrija u serumu
Ifirmacombi is unlikely to affect your ability to drive or use machines.
Ifirmacombi ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit).
U pretkliničkim ispitivanjima sigurnosti primjene visoke doze irbesartana (≥ 250 mg/kg/dan u štakora i ≥ 100 mg/kg/dan u makaki majmuna) uzrokovale su smanjenje vrijednosti crvenih krvnih stanica (eritrocita, hemoglobina, hematokrita).
Tables 2 and 3 below detail the adverse reactions reported with the individual components of Ifirmacombi.
Tablice 2 i 3 prikazuju nuspojave prijavljene za pojedinačne komponente lijeka Ifirmacombi.
At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion.
Pri vrlo visokim dozama (≥ 500 mg/kg/dan) irbesartan je izazvao degenerativne promjene na bubrezima (poput intersticijskog nefritisa, tubularne distenzije, bazofilnih tubula, povećane koncentracije uree i kreatinina u plazmi) u štakora i makaki majmuna, što se smatra sekundarnim učinkom hipotenzivnog učinka lijeka koji dovodi do smanjenja perfuzije bubrega.
When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Ako se utvrdi trudnoća, treba odmah prekinuti liječenje antagonistima receptora angiotenzina II te treba, ako je to primjereno, započeti s alternativnom terapijom (vidjeti dijelove 4.3 i 4.6).
Uncommon: Not known:
Često: Nije poznato:
Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).
Preporučuje se pratiti razinu kalija u serumu u rizičnih bolesnika (vidjeti dio 4.4).
Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites.
Irbesartan ne inhibira ACE (kininazu II), enzim koji generira angiotenzin II te degradira bradikinin u neaktivne metabolite.
In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5).
U bolesnika čiji vaskularni tonus i funkcija bubrega ovise najviše o aktivnosti renin-angiotenzinaldosteronskog sustava (npr. bolesnici s teškim kongestivnim zatajenjem srca ili postojećom bolesti bubrega, uključujući stenozu bubrežne arterije) liječenje inhibitorima angiotenzin konvertirajućeg enzima, ili antagonistima receptora angiotenzina II koji utječu na taj sustav, bilo je povezano s pojavom akutne hipotenzije, azotemije, oligurije i, rijetko, akutnog zatajenja bubrega (vidjeti dio 4.5).
Other antihypertensive agents:
Ostali antihipertenzivni lijekovi:
The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH.
Rizik od razvoja hipokalijemije najveći je u bolesnika s cirozom jetre, u bolesnika s pojačanom diurezom, u bolesnika koji peroralno uzimaju premalo elektrolita i u bolesnika koji istodobno uzimaju kortikosteroide ili adrenokortikotropne hormone (ACTH).
As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Kao što je to slučaj i s ostalim vazodilatatorima, poseban oprez indiciran je u bolesnika s aortnom ili mitralnom stenozom ili opstruktivnom hipertrofičnom kardiomiopatijom.
Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria
Nije poznato: reakcije preosjetljivosti kao što su angioedem, osip, urtikarija
Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled trials.
Tablici 1 prikazane su nuspojave prikupljene spontanim prijavljivanjem te u placebom kontroliranim ispitivanjima.
C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Nakon peroralne ili i.v. primjene C irbesartana oko 20% radioaktivnosti pojavilo se u urinu, a ostatak u stolici.
The frequency of the side effects listed below is defined using the following convention: Common: may affect up to 1 in 10 people
Učestalost dolje navedenih nuspojava definirana je na sljedeći način: Često: mogu se javiti u manje od 1 na 10 osoba Manje često: mogu se javiti u manje od 1 na 100 osoba
Ifirmacombi is for oral use.
Ifirmacombi namijenjen je za primjenu kroz usta.
Due to the hydrochlorothiazide component, Ifirmacombi is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/min).
Zbog hidroklorotiazida u sastavu lijeka, Ifirmacombi se ne preporučuje bolesnicima s teško oštećenom funkcijom bubrega (klirens kreatinina < 30 ml/min.).
If this dose does not help to reduce your blood pressure as required, the doctor may prescribe Ifirmacombi 300 mg/25 mg to you.
Ako Vam ova doza ne pomogne u snižavanju krvnog tlaka koliko je potrebno, liječnik Vam može propisati Ifirmacombi 300 mg/25 mg.
Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth.
Ispitivanja irbesartana na životinjama pokazala su prolazne toksične učinke (povećana kavitacija bubrežne nakapnice, hidroureter ili potkožni edem) u fetusa štakora koji su se povukli nakon okota.
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Ifirmacombi.
Dodatne informacije o pojedinačnim komponentama lijeka: uz navedene nuspojave kombiniranog lijeka moguće nuspojave lijeka Ifirmacombi mogu biti i one prethodno prijavljene za pojedinačne komponente lijeka.
Therefore, the combination of lithium and Ifirmacombi is not recommended (see section 4.4).
Stoga se kombinacija litija i lijeka Ifirmacombi ne preporučuje (vidjeti dio 4.4).
When Ifirmacombi is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Kada Ifirmacombi uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati razine kalija, kreatinina i mokraćne kiseline u serumu.
Uncommon syncope, hypotension, tachycardia, oedema
Manje često: sinkopa, hipotenzija, tahikardija, edem
Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Nesteroidni protuupalni lijekovi: u nekih bolesnika primjena nesteroidnih protuupalnih lijekova može smanjiti diuretski, natriuretski i antihipertenzivni učinak tiazida;
Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.
Znaci koji upozoravaju na neravnotežu tekućine ili elektrolita su suhoća u ustima, žeđ, slabost, letargija, omamljenost, nemir, bol ili grčevi u mišićima, mišićna slabost, hipotenzija, oligurija, tahikardija i gastrointestinalni poremećaji poput mučnine i povraćanja.
When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of non-black patients.
Kad se irbesartan primjeni zajedno s malom dozom hidroklorotiazida (primjerice 12,5 mg na dan), antihipertenzivni učinak u crnaca približava se učinku u drugih rasa.
Not known: postural hypotension
Nije poznato: posturalna hipotenzija
If this dose does not help to reduce your blood pressure as required, the doctor may prescribe Ifirmacombi 300 mg/12.5 mg to you.
Ako Vam ova doza ne pomogne u snižavanju krvnog tlaka koliko je potrebno, liječnik Vam može propisati Ifirmacombi 300 mg/12,5 mg.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists.
Povećan je rizik od teške hipotenzije i insuficijencije bubrega u bolesnika s obostranom stenozom bubrežnih arterija ili stenozom arterije u jedinom funkcionalnom bubregu koji su liječeni inhibitorima angiotenzin konvertirajućeg enzima ili antagonistima receptora angiotenzina II.
Aliskiren-containing products or ACE-inhibitors:
Lijekovi koji sadrže aliskiren ili ACE inhibitori:
How to take Ifirmacombi
Kako uzimati Ifirmacombi
You should also tell your doctor: - if you are on a low-salt diet - if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Ifirmacombi) - if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal - if you are going to have an operation (surgery) or be given anaesthetics - if you have changes in your vision or pain in one or both of your eyes while taking Ifirmacombi.
Svog liječnika također trebate obavijestiti: - ako ste na dijeti s malim unosom soli - ako imate simptome kao što su abnormalna žeđ, suha usta, opća slabost, omamljenost, grčevi ili bol u mišićima, mučnina, povraćanje ili abnormalno brz srčani ritam jer oni mogu upućivati na pretjerani učinak hidroklorotiazida (sastojak lijeka Ifirmacombi) - ako iskusite povećanu osjetljivost kože na sunce s pojavom simptoma sunčanih opeklina (kao što su crvenilo kože, svrbež, oticanje, plikovi), a pojavljuju se brže nego što je normalno - ako trebate ići na bilo kakvu operaciju ili trebate primiti anestetike - ako Vam se mijenja vid ili osjećate bol u jednom ili oba oka pri uzimanju lijeka Ifirmacombi.
Symptomatic hypotension may be expected to occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Simptomatska hipotenzija može se očekivati u bolesnika s hipovolemijom i/ili hiponatrijemijom zbog snažne terapije diureticima, smanjenog unosa soli, proljeva ili povraćanja.
Ifirmacombi contains sodium
Ifirmacombi sadrži natrij
Ifirmacombi should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Ifirmacombi ne smiju uzimati bolesnici s teško oštećenom funkcijom bubrega (klirens kreatinina < 30 ml/min) (vidjeti dio 4.3).
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed): - kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system; - slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit); - stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
Sljedeće promjene, zabilježene u štakora i makaki majmuna, koji su dobivali kombinaciju irbesartan/hidroklorotiazid u dozama od 10/10 i 90/90 mg/kg/dan, također su uočene i kod pojedinačne primjene ovih lijekova i/ili su bile sekundarne sniženju krvnog tlaka (nisu zabilježene značajne toksikološke interakcije): - promjene funkcije bubrega, karakterizirane blagim porastom razine ureje i kreatinina u serumu kao i hiperplazijom/hipertrofijom jukstaglomerularnog aparata što je izravna posljedica interakcije irbesartana s renin-angiotenzinskim sustavom; - blago sniženje eritrocitnih parametara (eritrociti, hemoglobin, hematokrit); - diskoloracija želuca, ulceracije i fokalna nekroza sluznice želuca primijećene su u nekoliko štakora tijekom šestomjesečnog ispitivanja toksičnosti nakon doza od 90 mg/kg/dan irbesartana,
The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p < 0.0001).
Srednja početna vrijednost krvnog tlaka bila je približno 172/113 mmHg u svakoj skupini, a smanjivanje sistoličkog/dijastoličkog tlaka u sjedećem položaju u pet tjedana iznosilo je 30,8/24,0 mmHg za irbesartan/hidroklorotiazid te 21,1/19,3 mmHg za irbesartan (p < 0,0001).
Side effects associated with hydrochlorothiazide alone Skin and lip cancer (non-melanoma skin cancer); loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or buildup of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.
Nuspojave povezane sa samim hidroklorotiazidom Rak kože i usana (nemelanomski rak kože); gubitak apetita, iritacija želuca, grčevi u želucu, konstipacija, žutica (žućkasta boja kože i/ili bjeloočnica), upala gušterače koju karakterizira jaka bol u gornjem dijelu trbuha, često s mučninom i povraćanjem, poremećaji spavanja, depresija, zamagljeni vid, smanjenje broja bijelih krvnih stanica što može rezultirati čestim infekcijama i vrućicom, smanjenje broja trombocita (krvne stanice neophodne za zgrušavanje krvi), smanjenje broja crvenih krvnih stanica (anemija) praćeno umorom, glavoboljom, nedostatkom zraka prilikom vježbanja, omaglicom i blijedim izgledom, bolest bubrega, problemi s plućima uključujući upalu pluća i nakupljanje tekućine u plućima, povećana osjetljivost kože na sunce, upala krvnih žila, kožna bolest koju karakterizira ljuštenje kože po cijelom tijelu, kožni eritemski lupus koji se očituje kao osip koji se javlja na licu, vratu i vlasištu, alergijske reakcije, slabost i spazam mišića, promjene brzine otkucaja srca, pad krvnog tlaka nakon promjene položaja tijela, oticanje žlijezda slinovnica, visoka vrijednost šećera u krvi, šećer u mokraći, povećanje nekih vrsta masnoća u krvi, visoke koncentracije mokraćne kiseline u krvi što može dovesti do gihta.
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Ifirmacombi (see section 4.5).
Diuretici koji štede kalij, nadomjesci kalija ili nadomjesci soli koji sadrže kalij moraju se s oprezom istodobno primjenjivati s lijekom Ifirmacombi (vidjeti dio 4.5).
Although not specifically studied with the Ifirmacombi, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Iako nisu provedena specifična ispitivanja s lijekom Ifirmacombi, ni s irbesartanom ni s hidroklorotiazidom nije primijećen povratak veće hipertenzije (rebound).
While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angle-closure glaucoma have been reported so far with hydrochlorothiazide.
Sa hidroklorotiazidom kao sulfonamidom zabilježeni su samo izolirani slučajevi akutnog glaukoma zatvorenog kuta.
The two active ingredients in Ifirmacombi work together to lower blood pressure further than if either was given alone.
Dvije djelatne tvari lijeka Ifirmacombi zajedno snažnije djeluju na sniženje krvnog tlaka nego kad se daju pojedinačno.
As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.
Kao u svih bolesnika koji uzimaju diuretike, potrebno je periodički i u primjerenim intervalima kontrolirati razinu serumskih elektrolita.
Not known: pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite
Nije poznato: pankreatitis, anoreksija, proljev, konstipacija, iritacija želuca, sijaloadenitis, gubitak apetita
Acute Myopia and Secondary Acute Angle-Closure Glaucoma:
Akutna miopija i sekundarni glaukom zatvorenog kuta:
Common:
Općenito:
Common: Not known abnormal urination impaired renal function including isolated cases of renal failure in patients at risk (see section 4.4)
abnormalnosti mokrenja oslabljena bubrežna funkcija uključujući izolirane slučajeve bubrežnog zatajenja u rizičnih bolesnika (vidjeti dio 4.4)
Not known: weakness, muscle spasm
Nije poznato: slabost, mišićni spazam
Ifirmacombi is a combination of two active substances, irbesartan and hydrochlorothiazide.
Ifirmacombi je kombinacija dvije djelatne tvari, irbesartana i hidroklorotiazida.
Not known: transient blurred vision, xanthopsia, acute myopia and secondary acute angle-closure glaucoma
Nije poznato: prolazno zamagljeni vid, ksantopsija, akutna miopija i sekundarni glaukom zatvorenog kuta
There is no clinical experience with Ifirmacombi in patients with hepatic impairment.
Nema kliničkog iskustva s primjenom lijeka Ifirmacombi u bolesnika s oštećenom funkcijom jetre.
Hypotension - Volume-depleted patients:
Hipotenzija - Bolesnici s hipovolemijom:
You may need to have blood checks if you take: - potassium supplements - salt substitutes containing potassium - potassium sparing medicines or other diuretics (water tablets) - some laxatives - medicines for the treatment of gout - therapeutic vitamin D supplements - medicines to control heart rhythm - medicines for diabetes (oral agents or insulins) - carbamazepine (a medicine for the treatment of epilepsy).
- nadomjestke kalija - nadomjestke soli koji sadrže kalij - lijekove koji štede kalij ili druge diuretike (tablete za mokrenje) - neke laksative - lijekove za liječenje gihta - terapijske nadomjestke vitamina D - lijekove za kontrolu srčanog ritma - lijekove za šećernu bolest (oralni pripravci ili inzulin) - karbamazepin (lijek za liječenje epilepsije).
Uncommon side effects (may affect up to 1 in 100 people): - diarrhoea - low blood pressure - fainting - heart rate increased - flushing - swelling - sexual dysfunction (problems with sexual performance) - blood tests may show lowered levels of potassium and sodium in your blood.
Manje česte nuspojave (mogu se javiti u manje od 1 na 100 osoba): - proljev - nizak krvni tlak - nesvjestica - ubrzani otkucaji srca - crvenilo praćeno osjećajem vrućine - oticanje - problemi sa seksualnom funkcijom - krvne pretrage mogu pokazati smanjene vrijednosti kalija i natrija u krvi.
Ifirmacombi is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Ifirmacombi je kombinacija irbesartana, antagonista receptora angiotenzina II i hidroklorotiazida, tiazidskog diuretika.
Angiotensin II Receptor Antagonists (AIIRAs):
Antagonisti receptora angiotenzina II
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially "sodiumfree".
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
When measured by ambulatory blood pressure monitoring, the trough to peak effects of Ifirmacombi 150 mg/12.5 mg were 100%.
Na osnovi ambulantnih mjerenja krvnog tlaka, učinci najniže i najviše koncentracije pri primjeni lijeka Ifirmacombi 150 mg/12,5 mg iznosili su 100%.
Renal impairment and kidney transplantation:
Oštećena funkcija bubrega i transplantacija bubrega:
Hydrochlorothirazide
Hidroklorotiazid
Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.
Anti-doping test: Hidroklorotiazid u sastavu lijeka može dovesti do pozitivnog analitičkog rezultata antidoping testa.
Ifirmacombi is not indicated in patients with severe hepatic impairment.
Ifirmacombi nije indiciran u bolesnika s teško oštećenom funkcijom jetre.
Not known: interstitial nephritis, renal dysfunction
Nije poznato: intersticijski nefritis, bubrežna disfunkcija